keyword
MENU ▼
Read by QxMD icon Read
search

Asthma copd

keyword
https://www.readbyqxmd.com/read/27922751/new-therapies-for-asthma-and-copd
#1
Nicholas J Gross, Peter J Barnes
Asthma and COPD (chronic obstructive pulmonary disease) are two common diseases for which current treatments are less than optimal and for which new drugs are greatly needed. Better understanding of the cellular and molecular mechanisms of these diseases has identified new targets for therapy and several new drugs are in development. Although most new treatments on the market are improvements in existing classes of drug or new combination of treatments, the clinicaltrials.gov website indicates 50 and 100 new medications for both asthma and COPD and many of these are entirely new...
December 6, 2016: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27921210/tight-junctions-in-pulmonary-epithelia-during-lung-inflammation
#2
REVIEW
Oliver H Wittekindt
Inflammatory lung diseases like asthma bronchiale, chronic obstructive pulmonary disease and allergic airway inflammation are widespread public diseases that constitute an enormous burden to the health systems. Mainly classified as inflammatory diseases, the treatment focuses on strategies interfering with local inflammatory responses by the immune system. Inflammatory lung diseases predispose patients to severe lung failures like alveolar oedema, respiratory distress syndrome and acute lung injury. These life-threatening syndromes are caused by increased permeability of the alveolar and airway epithelium and exudate formation...
December 5, 2016: Pflügers Archiv: European Journal of Physiology
https://www.readbyqxmd.com/read/27920974/a-case-report-of-malignant-obesity-hypoventilation-syndrome-a-weighty-problem-in-our-icus
#3
Michael Tatusov, Joshua J Joseph, Brian M Cuneo
INTRODUCTION: The obesity epidemic is reflected by increasing numbers of morbidly obese patients being admitted to intensive care units (ICUs). These are complicated patients whose care involves many diagnostic and treatment challenges. We are presenting a fatal case of super obesity, hypoventilation, and multi-organ failure known as malignant obesity hypoventilation syndrome (MOHS). CASE PRESENTATION: 35 year old African American gentleman with a body mass index (BMI) of 115 kg/m(2) presented to the hospital with respiratory distress...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/27919487/inverse-comorbidity-in-multiple-sclerosis-findings-in-a-complete-nationwide-cohort
#4
Anja Thormann, Nils Koch-Henriksen, Bjarne Laursen, Per Soelberg Sørensen, Melinda Magyari
BACKGROUND: Inverse comorbidity is disease occurring at lower rates than expected among persons with a given index disease. The objective was to identify inverse comorbidity in MS. METHODS: We performed a combined case-control and cohort study in a total nationwide cohort of cases with clinical onset of MS 1980-2005. We randomly matched each MS-case with five population controls. Comorbidity data were obtained from multiple, independent nationwide registries. Cases and controls were followed from January 1977 to the index date, and from the index date through December 2012...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27917014/contextual-ecological-and-organizational-variations-in-risk-adjusted-copd-and-asthma-hospitalization-rates-of-rural-medicare-beneficiaries
#5
Thomas T H Wan, Yi-Ling Lin, Judith Ortiz
The purpose of this study is to examine what factors contributing to the variability in chronic obstructive pulmonary disorder (COPD) and asthma hospitalization rates when the influence of patient characteristics is being simultaneously considered by applying a risk adjustment method. A longitudinal analysis of COPD and asthma hospitalization of rural Medicare beneficiaries in 427 rural health clinics (RHCs) was conducted utilizing administrative data and inpatient and outpatient claims from Region 4. The repeated measures of risk-adjusted COPD and asthma admission rate were analyzed by growth curve modeling...
2016: Research in the Sociology of Health Care
https://www.readbyqxmd.com/read/27914950/access-to-medications-for-medicare-enrollees-related-to-race-ethnicity-results-from-the-2013-medicare-current-beneficiary-survey
#6
Deborah A Taira, Chengli Shen, Marshaleen King, Doug Landsittel, Mary Helen Mays, Tetine Sentell, Janet Southerland
BACKGROUND: Prescription medications are taken by millions of Americans to manage chronic conditions and treat acute conditions. These medications, however, are not equally accessible to all. OBJECTIVE: To examine medication access by race/ethnicity among Medicare beneficiaries. METHODS: Using the 2013 Medicare Current Beneficiary Survey (n = 10.515), this study examined access to medications related to race/ethnicity, comparing non-Hispanic blacks and Hispanics to whites...
November 23, 2016: Research in Social & Administrative Pharmacy: RSAP
https://www.readbyqxmd.com/read/27913298/a-novel-monoclonal-antibody-suitable-for-the-detection-of-leukotriene-b4
#7
Steffi Lütkecosmann, Axel Warsinke, Winfried Tschöpe, Rüdiger Eichler, Katja Hanack
Leukotriene B4 as an inflammatory mediator is an important biomarker for different respiratory diseases like asthma, chronic obstructive pulmonary disease or cystic lung fibrosis. Therefore the detection of LTB4 is helpful in the diagnosis of these pulmonary diseases. However, until now its determination in exhaled breath condensates suffers from problems of accuracy. Reasons for that could be improper sample collection and preparation methods of condensates and the lack of consistently assay specificity and reproducibility of the used immunoassay detection system...
November 29, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27908909/dtb-select-12-december-2016
#8
(no author information available yet)
Azithromycin of no benefit for asthma attacks ● Risk of heart failure with NSAIDs ● Bisphosphonates and steroid-induced osteoporosis ● Triple therapy for moderate-to-severe COPD: marginal benefits ● Much data on adverse events remains unpublished ● Rising placebo response rates in antidepressant trials a 'myth' ● Prenatal fetal RhD testing recommended.
December 1, 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27905850/asthma-like-features-and-chronic-obstructive-pulmonary-disease
#9
Gareth Hynes, Ian D Pavord
No abstract text is available yet for this article.
December 1, 2016: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27903208/early-experience-of-a-new-extracorporeal-carbon-dioxide-removal-device-for-acute-hypercapnic-respiratory-failure
#10
Ravindranath Tiruvoipati, Hergen Buscher, James Winearls, Jeff Breeding, Debasish Ghosh, Shimonti Chaterjee, Gary Braun, Eldho Paul, John F Fraser, John Botha
BACKGROUND: Recent advances in the technology of extracorporeal respiratory assist systems have led to a renewed interest in extracorporeal carbon dioxide removal (ECCOR). The Hemolung is a new, low-flow, venovenous, minimally invasive, partial ECCOR device that has recently been introduced to clinical practice to aid in avoiding invasive ventilation or to facilitate lung-protective ventilation. OBJECTIVE: We report our early experience on use, efficacy and safety of the Hemolung in three Australian intensive care units...
December 2016: Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine
https://www.readbyqxmd.com/read/27890989/the-burden-of-segregated-respiratory-diseases-in-india-and-the-quality-of-care-in-these-patients-results-from-the-asia-pacific-burden-of-respiratory-diseases-study
#11
Aloke Gopal Ghoshal, G D Ravindran, Paras Gangwal, Girish Rajadhyaksha, Sang-Heon Cho, Abdul Razak Bin Abdul Muttalif, Horng-Chyuan Lin, Sanguansak Thanaviratananich, Shalini Bagga, Rab Faruqi, Shiva Sajjan, Pradeep Shetty, Raeesuddin Syed, Kim K Hamrosi, De Yun Wang
BACKGROUND: Chronic respiratory diseases such as asthma, allergic rhinitis (AR), chronic obstructive pulmonary disease (COPD), and rhinosinusitis are becoming increasingly prevalent in the Asia-Pacific region. The Asia-Pacific Burden of Respiratory Diseases study examined the disease and economic burden of AR, asthma, COPD, and rhinosinusitis across the Asia-Pacific and more specifically India. OBJECTIVES: To estimate the proportion of adults receiving care for asthma, AR, COPD, and rhinosinusitis and assess the economic burden, both direct and indirect of these chronic respiratory disease...
November 2016: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/27889330/use-of-biologics-to-treat-acute-exacerbations-and-manage-disease-in-asthma-copd-and-ipf
#12
REVIEW
Lynne A Murray, Chris Grainge, Peter A Wark, Darryl A Knight
A common feature of chronic respiratory disease is the progressive decline in lung function. The decline can be indolent, or it can be accelerated by acute exacerbations, whereby the patient experiences a pronounced worsening of disease symptoms. Moreover, acute exacerbations may also be a marker of insufficient disease management. The underlying cause of an acute exacerbation can be due to insults such as pathogens or environmental pollutants, or the cause can be unknown. For each acute exacerbation, the patient may require medical intervention such as rescue medication, or in more severe cases, hospitalization and ventilation and have an increased risk of death...
November 24, 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27888348/pathogenesis-of-copd-and-asthma
#13
Clive Page, Blaze O'Shaughnessy, Peter Barnes
Asthma and COPD remain two diseases of the respiratory tract with unmet medical needs. This review considers the current state of play with respect to what is known about the underlying pathogenesis of these two chronic inflammatory diseases of the lung. The review highlights why they are different conditions requiring different approaches to treatment and provides a backdrop for the subsequent chapters in this volume discussing recent advances in the pharmacology and treatment of asthma and COPD.
November 26, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27888157/curcumin-use-in-pulmonary-diseases-state-of-the-art-and-future-perspectives
#14
REVIEW
Diana Lelli, Amirhossein Sahebkar, Thomas P Johnston, Claudio Pedone
Curcumin (diferuloylmethane) is a yellow pigment present in the spice turmeric (Curcuma longa). It has been used for centuries in Ayurveda (Indian traditional medicine) for the treatment of several diseases. Over the last several decades, the therapeutic properties of curcumin have slowly been elucidated. It has been shown that curcumin has pleiotropic effects, regulating transcription factors (e.g., NF-kB), cytokines (e.g., IL6, TNF-alpha), adhesion molecules (e.g., ICAM-1), and enzymes (e.g., MMPs) that play a major role in inflammation and cancerogenesis...
November 22, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27883375/analysis-of-risk-factors-for-severe-acute-respiratory-infection-and-pneumonia-and-among-adult-patients-with-acute-respiratory-illness-during-2011-2014-influenza-seasons-in-korea
#15
Seong Hui Kang, Hee Jin Cheong, Joon Young Song, Ji Yun Noh, Ji Ho Jeon, Min Joo Choi, Jacob Lee, Yu Bin Seo, Jin Soo Lee, Seong Heon Wie, Hye Won Jeong, Young Keun Kim, Kyung Hwa Park, Shin Woo Kim, Eun Joo Jeong, Sun Hee Lee, Won Suk Choi, Woo Joo Kim
BACKGROUND: The World Health Organization recommends the surveillance of influenza-like illness (ILI) and severe acute respiratory infection (SARI) to respond effectively to both seasonal influenza epidemics and pandemics. In Korea, the "Hospital-based Influenza Morbidity and Mortality (HIMM)" surveillance system has been operated to monitor ILI and SARI occurrences. MATERIALS AND METHODS: A multi-center prospective observational study was conducted. Adult patients with acute respiratory infection (ARI) were enrolled during the 2011-2012, 2012-2013, and 2013-2014 influenza seasons at the 10 university hospitals using the HIMM surveillance system...
November 22, 2016: Infection & Chemotherapy
https://www.readbyqxmd.com/read/27883002/a-randomised-open-label-cross-over-study-of-inhaler-errors-preference-and-time-to-achieve-correct-inhaler-use-in-patients-with-copd-or-asthma-comparison-of-ellipta-with-other-inhaler-devices
#16
Job van der Palen, Mike Thomas, Henry Chrystyn, Raj K Sharma, Paul Dlpm van der Valk, Martijn Goosens, Tom Wilkinson, Carol Stonham, Anoop J Chauhan, Varsha Imber, Chang-Qing Zhu, Henrik Svedsater, Neil C Barnes
Errors in the use of different inhalers were investigated in patients naive to the devices under investigation in a multicentre, single-visit, randomised, open-label, cross-over study. Patients with chronic obstructive pulmonary disease (COPD) or asthma were assigned to ELLIPTA vs DISKUS (Accuhaler), metered-dose inhaler (MDI) or Turbuhaler. Patients with COPD were also assigned to ELLIPTA vs Handihaler or Breezhaler. Patients demonstrated inhaler use after reading the patient information leaflet (PIL). A trained investigator assessed critical errors (i...
November 24, 2016: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/27881264/quality-of-life-and-economic-burden-of-respiratory-disease-in-asia-pacific-asia-pacific-burden-of-respiratory-diseases-study
#17
De Yun Wang, Aloke Gopal Ghoshal, Abdul Razak Bin Abdul Muttalif, Horng-Chyuan Lin, Sanguansak Thanaviratananich, Shalini Bagga, Rab Faruqi, Shiva Sajjan, Alan J M Brnabic, Francis C Dehle, Sang-Heon Cho
OBJECTIVES: Asia-Pacific Burden of Respiratory Diseases is a cross-sectional, observational study examining the burden of disease in adults with respiratory diseases across six countries. The aim of this study was to describe health care resource use (HCRU), work impairment, cost burden, and health-related quality of life (HRQOL) associated with respiratory disease in the Asia-Pacific. METHODS: Consecutive participants aged 18 years or older with a primary diagnosis of asthma, allergic rhinitis, chronic obstructive pulmonary disease, or rhinosinusitis were enrolled...
May 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27880632/burden-of-multiple-chronic-conditions-in-delaware-2011-2014
#18
Sangeeta Gupta
The objective of this study was to use data from the Behavioral Risk Factor Surveillance System (BRFSS) to examine the prevalence of multiple chronic conditions (MCC) by select sociodemographic groups and determine the prevalence of most common MCC dyads and triads among Delaware adults. Combined data for 2011 through 2014 from BRFSS (n = 18,052) were analyzed to determine prevalence of MCC. Delaware adults were categorized as having 0, 1, 2, or 3 or more of the following diagnosed chronic conditions: angina, arthritis, asthma, cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, high blood pressure, high cholesterol, myocardial infarction (heart attack), obesity, or stroke...
November 23, 2016: Preventing Chronic Disease
https://www.readbyqxmd.com/read/27879970/mortality-hospital-days-and-expenditures-attributable-to-ambient-air-pollution-from-particulate-matter-in-israel
#19
Gary M Ginsberg, Ehud Kaliner, Itamar Grotto
BACKGROUND: Worldwide, ambient air pollution accounts for around 3.7 million deaths annually. Measuring the burden of disease is important not just for advocacy but also is a first step towards carrying out a full cost-utility analysis in order to prioritise technological interventions that are available to reduce air pollution (and subsequent morbidity and mortality) from industrial, power generating and vehicular sources. METHODS: We calculated the average national exposure to particulate matter particles less than 2...
2016: Israel Journal of Health Policy Research
https://www.readbyqxmd.com/read/27878470/%C3%AE-2-agonists
#20
Charlotte K Billington, Raymond B Penn, Ian P Hall
History suggests β agonists, the cognate ligand of the β2 adrenoceptor, have been used as bronchodilators for around 5,000 years, and β agonists remain today the frontline treatment for asthma and chronic obstructive pulmonary disease (COPD). The β agonists used clinically today are the products of significant expenditure and over 100 year's intensive research aimed at minimizing side effects and enhancing therapeutic usefulness. The respiratory physician now has a therapeutic toolbox of long acting β agonists to prophylactically manage bronchoconstriction, and short acting β agonists to relieve acute exacerbations...
November 23, 2016: Handbook of Experimental Pharmacology
keyword
keyword
25779
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"